September 28, 2012
A ruling that the U.S. Food and Drug Administration improperly classified a drug-and-device combination product as a drug — a more expensive designation that many sponsors try to avoid — may not change how the FDA designates combo products, experts say, but should encourage more unhappy sponsors to appeal.